Suppr超能文献

巨大男性泌乳素瘤的神经、精神、眼科和内分泌并发症:阿尔及利亚人群的一项观察性研究。

Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population.

作者信息

Chentli Farida, Azzoug Said, Daffeur Katia, Akkache Lina, Zellagui Hadjer, Haddad Meriem, Kalafate Nadia

机构信息

Department of Endocrine and Metabolic Diseases, Bab El Oued Teaching Hospital, University of Medicine, Algiers, Algeria.

出版信息

Indian J Endocrinol Metab. 2015 May-Jun;19(3):359-63. doi: 10.4103/2230-8210.152771.

Abstract

INTRODUCTION

Prolactinomas are less frequent, but more invasive in males. Giant ones (≥4 cm) are extremely rare in literature. Their neurological, psychiatric and endocrine complications are life threatening. Our aim was to report the largest mono center series in order to analyze their frequency, their characteristics, and their complications.

SUBJECTS AND METHODS

All patients had clinical examination, hormonal, ophthalmological, and radiological assessment based on computed tomography scan and cerebral magnetic resonance imaging. Positive diagnosis was based on clinical symptoms, high prolactin ± immunohistochemy study. Mixed adenomas were excluded by hormonal exploration and immunohistochemy. For those who received medical treatment only, a reduction in tumor size was considered a supplementary positive point for the diagnosis.

RESULTS

Among 154 male prolactinomas seen between 1987 and 2013, we observed 44 giant tumors (28.5%). Median age = 36 years, and 38.3% were under 30. Median tumor height = 53.95 mm (40-130) and median prolactin = 15,715 ng/ml (n < 20). Solid and cystic aspect ± calcifications was observed in 25%. 42 had cavernous sinuses invasion. Other invasions were: Posterior= 65.9%, anterior= 63.6%, temporal= 15.9% and frontal = 9%. For endocrine complications: Hypogonadism = 98.4%, thyrotroph and corticotroph deficits were seen in respectively 34%, and 32%. Posterior pituitary insufficiency was observed in one case. For ophthalmological complications: Optic atrophy = 46%, Ptosis = 6.8%, diplopia/strabismus = 4.5%. Neurological complications were: Memory loss and/or unconsciousness = 18.2%, epilepsy = 15.9%, frontal syndrome = 9% and obstructive hydrocephalus = 6.8%.

CONCLUSION

Giant prolactinomas account for 28% in our population. Severe neurological complications are frequent. But, obstructive hydrocephalus is rare, which argues for a slow progression.

摘要

引言

泌乳素瘤在男性中较为少见,但侵袭性更强。巨大泌乳素瘤(≥4厘米)在文献中极为罕见。其神经、精神及内分泌并发症会危及生命。我们的目的是报告最大的单中心系列病例,以分析其发生率、特征及并发症。

研究对象与方法

所有患者均接受了临床检查、激素检查、眼科检查以及基于计算机断层扫描和脑磁共振成像的放射学评估。阳性诊断基于临床症状、高泌乳素水平±免疫组化研究。通过激素检测和免疫组化排除混合性腺瘤。对于仅接受药物治疗的患者,肿瘤大小缩小被视为诊断的补充阳性指标。

结果

在1987年至2013年间诊治的154例男性泌乳素瘤患者中,我们观察到44例巨大肿瘤(28.5%)。中位年龄为36岁,38.3%的患者年龄在30岁以下。中位肿瘤高度为53.95毫米(40 - 130),中位泌乳素水平为15,715纳克/毫升(n < 20)。25%的肿瘤表现为实性和囊性外观±钙化。42例患者出现海绵窦侵袭。其他侵袭情况为:后方侵袭占65.9%,前方侵袭占63.6%,颞叶侵袭占15.9%,额叶侵袭占9%。内分泌并发症方面:性腺功能减退占98.4%,促甲状腺激素和促肾上腺皮质激素缺乏分别占34%和32%。有1例患者出现垂体后叶功能不全。眼科并发症方面:视神经萎缩占46%,上睑下垂占6.8%,复视/斜视占4.5%。神经并发症包括:记忆力减退和/或意识丧失占18.2%,癫痫占15.9%,额叶综合征占9%,梗阻性脑积水占6.8%。

结论

巨大泌乳素瘤在我们的研究人群中占28%。严重的神经并发症很常见。但是,梗阻性脑积水罕见,这表明肿瘤进展缓慢。

相似文献

2
Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma.
Clin Med Insights Case Rep. 2012;5:115-8. doi: 10.4137/CCRep.S9675. Epub 2012 Jul 16.
3
Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.
Clin Med Insights Endocrinol Diabetes. 2020 Jun 4;13:1179551420926181. doi: 10.1177/1179551420926181. eCollection 2020.
4
Giant prolactinomas, a detailed analysis of 196 adult cases.
Pituitary. 2023 Oct;26(5):529-537. doi: 10.1007/s11102-023-01337-0. Epub 2023 Aug 7.
5
Long-term outcome of multimodal therapy for giant prolactinomas.
Endocrine. 2017 Jan;55(1):231-238. doi: 10.1007/s12020-016-1129-9. Epub 2016 Oct 4.
6
Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1.
Front Endocrinol (Lausanne). 2019 Aug 28;10:582. doi: 10.3389/fendo.2019.00582. eCollection 2019.
7
GIANT PROLACTINOMA. A CASE REPORT.
Cesk Slov Oftalmol. 2023 Spring;79(3):143-148. doi: 10.31348/2023/20.
8
Our experience in prolactinomas larger than 60mm.
Endocrinol Diabetes Nutr (Engl Ed). 2021 Jan;68(1):3-10. doi: 10.1016/j.endinu.2020.03.012. Epub 2020 Aug 26.
9
General seizures revealing macro-adenomas secreting prolactin or prolactin and growth hormone in men.
Indian J Endocrinol Metab. 2014 May;18(3):361-3. doi: 10.4103/2230-8210.131185.
10
Giant prolactinomas: clinical management and long-term follow up.
J Neurosurg. 2002 Aug;97(2):299-306. doi: 10.3171/jns.2002.97.2.0299.

引用本文的文献

1
Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.
Clin Med Insights Endocrinol Diabetes. 2020 Jun 4;13:1179551420926181. doi: 10.1177/1179551420926181. eCollection 2020.
2
Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1.
Front Endocrinol (Lausanne). 2019 Aug 28;10:582. doi: 10.3389/fendo.2019.00582. eCollection 2019.

本文引用的文献

1
Cabergoline treatment in invasive giant prolactinoma.
Clin Med Insights Case Rep. 2014 Jun 19;7:49-51. doi: 10.4137/CCRep.S15790. eCollection 2014.
2
Bacterial meningitis as a first presentation of pituitary macroprolactinoma.
Endocrinol Diabetes Metab Case Rep. 2014;2014:140028. doi: 10.1530/EDM-14-0028. Epub 2014 May 1.
3
General seizures revealing macro-adenomas secreting prolactin or prolactin and growth hormone in men.
Indian J Endocrinol Metab. 2014 May;18(3):361-3. doi: 10.4103/2230-8210.131185.
4
Giant invasive basal skull prolactinoma with CSF rhinorrhoea and meningitis.
Clin Neurol Neurosurg. 2014 May;120:145-6. doi: 10.1016/j.clineuro.2014.02.028. Epub 2014 Mar 13.
5
Therapy of endocrine disease: the challenges in managing giant prolactinomas.
Eur J Endocrinol. 2014 Jun;170(6):R213-27. doi: 10.1530/EJE-14-0013. Epub 2014 Feb 17.
6
Suppurative meningitis: A life-threatening complication in male macroprolactinomas.
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S117-21. doi: 10.4103/2230-8210.119524.
7
Giant prolactinomas in women.
Eur J Endocrinol. 2013 Nov 22;170(1):31-8. doi: 10.1530/EJE-13-0503. Print 2014 Jan.
8
Giant prolactinomas: the therapeutic approach.
Clin Endocrinol (Oxf). 2013 Oct;79(4):447-56. doi: 10.1111/cen.12242. Epub 2013 Jun 11.
9
Giant prolactinoma: case report and review of literature.
J Diabetes Metab Disord. 2013 Jan 8;12(1):3. doi: 10.1186/2251-6581-12-3.
10
Rapid reduction with cystic transformation of invasive giant prolactinoma following short term low dose cabergoline.
Indian J Endocrinol Metab. 2012 Nov;16(6):1048-51. doi: 10.4103/2230-8210.103041.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验